

ASX ANNOUNCEMENT / MEDIA RELEASE ASX: (NXS)

Change of registered office

Sydney Australia Thursday, 6 July 2023: Next Science Limited (ASX: NXS) (**Next Science or Company**), a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health, advises, in accordance with ASX Listing Rule 3.14, of the relocation of its head office to the offices of the Company's lawyers, HWL Ebsworth, Level 14, Australia Square, 264-278 George Street, Sydney.

The decision to relocate the Company's head office aligns with the Company's previously announced strategic decision to move the Chief Executive Officer and Chief Financial Officer roles to the Company's office in Jacksonville, Florida, USA.

The Jacksonville office is the base for the Company's commercial activities, research and development (including its internal laboratory), and regulatory functions, as well as the supply chain and commercial operation of the DME Business. The office houses 50 staff out of a total US headcount of over 100 staff.

Effective 6 July 2023, the Company's registered office address and principal place of business in Australia is:

HWL Ebsworth Level 14, Australia Square 264-278 George Street Sydney NSW 2000 Ph +61 2 8607 5124

Further Information:

Martyn Jacobs

Head of Investor Relations Phone: +61 412 785 180

Email: mjacobs@nextscience.com

Authorised to be given to ASX by Judith Mitchell, Managing Director and CEO.

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. For further information visit: www.nextscience.com